

BOARD CHANGES

Melbourne, Australia, 30 October 2026: INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**), advises that Dr Geoff Cumming and Mary Harney have decided to retire as Non-Executive Directors of INOVIQ at the Annual General Meeting on 25 November 2026.

Commenting on his decision, Dr Geoff Cumming said: *"It has been an honour to serve as a Director of INOVIQ and to be part of its exciting journey as it advances innovative technologies which will make a meaningful difference to people's lives. I leave with enormous admiration for the team, confidence in the opportunities ahead and gratitude for having played a part in building the foundations for the Company's future success."*

Commenting on her decision, Mary Harney added: *"INOVIQ is unique in Australian biotech with a multi-asset platform across diagnostics and therapeutics. The foundations are there for success across many indications and in particular, unmet need in women's health. It's been a privilege to be part of and contribute to, that journey."*

INOVIQ Executive Chairman Peter Gunzburg added: *"Geoff and Mary's scientific knowledge and acumen, combined with Listed Company experience, have been essential in advancing INOVIQ's asset portfolio and growth strategy. On behalf of the Board and management team, we thank both Geoff and Mary for their respective contributions to INOVIQ."*

Concurrently INOVIQ announces the appointment of Andrew Chapman as a Non-Executive Director effective 2 November 2026.

Mr Chapman is the Founder of Merchant Funds Management and has over 25 years' experience in the financial services industry. Andrew has spent his career in the financial markets advising many biotech companies on capital raisings and financial markets strategy and execution. Mr Chapman is currently a Non-Executive Director of Argent BioPharma Ltd (ASX: RGT) and Neurotech International Ltd (ASX: NTI) and Chairman of Cycliq Group Ltd (ASX: CYQ). He holds a Bachelor of Commerce and a Post Graduate Diploma in Finance & Investment.

IIQ Executive Chairman Peter Gunzburg said: *"I am delighted Andrew is joining the board representing our second largest shareholder. We value his understanding of capital markets and as a long-term shareholder, he understands the history, progress and challenges facing a business such as ours. Andrew joins at an important time as we refocus our efforts to progress the development of our EXO-OC test and other development programs."*

As a result of the above changes, INOVIQ will issue an addendum to the existing Notice of Meeting for its upcoming AGM in the coming days. This addendum is necessary to reflect that Mary Harney is no longer standing for re-election and instead, Andrew Chapman will stand for election at the 2026 Annual General Meeting being held on 25 November 2026.

Authorised for release by the INOVIQ Limited Board of Directors.

FURTHER INFORMATION

Peter Gunzburg

Executive Chairman

E peter.gunzburg@gmail.com

M +61 412 927 773

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX: IIQ) is a leader in exosome technology advancing next-generation diagnostics and therapeutics that transform cancer care. Our product portfolio includes commercial-stage exosome isolation products, a clinical-stage diagnostic for early detection of ovarian cancer, and a cutting-edge preclinical CAR-exosome therapeutic program for solid tumours. INOVIQ is shaping the future of cancer detection and treatment to improve patient outcomes. For more information on INOVIQ, visit www.inoviq.com.

For personal use only